Insulet is trading higher today as investors digest recent updates regarding the company's upcoming third-quarter financial results, which are scheduled for release on November 4, 2026.
The stock continues to be monitored by analysts who maintain a consensus target price of $195.40 and a hold rating on the shares. While the company faces ongoing legal investigations regarding shareholder claims, it remains a focal point for market observers interested in its tubeless insulin delivery technology.